Publications
-
Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and
Citation: Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, Supparatpinyo K, Mohapi L, Gupta A, Benson Cam, Kim P, Fletcher CV on behalf of the ACTG A5279 Study Team. Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and efavirenz-pharmacokinetics-and-pharmacodynamics-in-hiv-infected-person. Clin Infect Dis. 2015 Oct 15;61(8):1322-7. doi: 10.1093/cid/civ464. Epub 2015 Jun 16. PMID: 26082504. PMCID: PMC4583578.
Date: 10/15/2015
Violence against women in selected areas of the United States
Citation: Montgomery BE, Rompalo A, Hughes J, Wang J, Haley D, Soto-Torres L, Chege W, Justman J, Kuo I, Golin C, Frew P, Mannheimer S, Hodder S. Violence against women in selected areas of the United States. Am J Public Health. 2015 Oct;105(10):2156-66. doi: 10.2105/AJPH.2014.302430. Epub 2015 Mar 19.
Date: 10/15/2015
Changes in bone mineral density after antiretroviral initiation with tenofovir disoproxil
Citation: Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T, Yang O, Dubé MP, Murphy RL, Stein JH, McComsey GA. Changes in bone mineral density after antiretroviral initiation with tenofovir disoproxil fumarate-emtricitabine plus atazanavir-ritonavir, darunavir-ritonavir, or raltegravir. J Infect Dis. 2015 Oct 15;212(8):1241-9. doi: 10.1093/infdis/jiv194. Epub 2015 May 5. PMID: 25948863. PMCID: PMC4577040.
Date: 10/15/2015
Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over
Citation: Nichols SL, Bethel J, Kapogiannis BG, Li T, Woods SP, Patton ED, Ren W, Thornton SE, Major-Wilson HO, Puga AM, Sleasman JW, Rudy BJ, Wilson CM, Garvie PA; Adolescent Medicine Trials Network for HIV/AIDS Interventions. Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV. J Neurovirol. 2016 Apr;22(2):218-30. doi: 10.1007/s13365-015-0389-0. Epub 2015 Oct 13. PMID: 26463526; PMCID: PMC4781894
Date: 10/13/2015
Altered monocyte phenotype in HIV-1 infection tends to normalize with integrase-inhibitor-based
Citation: McCausland MR, Juchnowski SM, Zidar DA, Kuritzkes DR, Andrade A, Sieg SF, Lederman MM, Funderburg NT. Altered monocyte phenotype in HIV-1 infection tends to normalize with integrase-inhibitor-based antiretroviral therapy. PLoS One. 2015 Oct 2;10(10):e0139474. doi: 10.1371/journal.pone.0139474. eCollection 2015. PMID: 26430882. PMCID: PMC4591977.
Date: 10/02/2015
Pre-cART elevation of CRP and CD4+ T-cell immune activation associated with HIV clinical progression
Citation: Balagopal A, Asmuth DM, Yang WT, Campbell TB, Gupte N, Smeaton L, Kanyama C, Grinsztejn B, Santos B, Supparatpinyo K, Badal-Faesen S, Lama JR, Lalloo UG, Zulu F, Pawar JS, Riviere C, Kumarasamy N, Hakim J, Li XD, Pollard RB, Semba RD, Thomas DL, Bollinger RC, Gupta A; ACTG PEARLS and NWCS 319 Study team. Pre-cART elevation of CRP and CD4+ T-cell immune activation associated with HIV clinical progression in a multinational case-cohort study. J Acquir Immune Defic Syndr. 2015 Oct 1;70(2):163-71. doi: 10.1097/QAI.0000000000000696. PMID: 26017661. PMCID: PMC4573329.
Date: 10/01/2015
Economic and epidemiological impact of early antiretroviral therapy initiation in India
Citation: Maddali MV, Dowdy DW, Gupta A, Shah M. Economic and epidemiological impact of early antiretroviral therapy initiation in India. Journal of the International AIDS Society. 2015 Oct 1;18:20217.
Date: 10/01/2015
Less bone loss with maraviroc- compared to tenofovir-containing antiretroviral therapy
Citation: Taiwo B, Berzins B, Chan E, Ribaudo HJ, Fichtenbaum C, Tsibris A, Klingman K, Eron J, Brown TT. Less bone loss with maraviroc- compared to tenofovir-containing antiretroviral therapy in the ACTG A5303 Study. Clin Infect Dis. 2015 Oct 1;61(7):1179-88. doi: 10.1093/cid/civ455. Epub 2015 Jun 9. PMID: 26060295. PMCID: PMC4560904.
Date: 10/01/2015
Chlamydia and gonorrhea in HIV-infected pregnant women and infant HIV transmission
Citation: Adachi K, Klausner JD, Bristow CC, Xu J, Ank B, Morgado MG, Watts DH, Weir F, Persing D, Mofenson LM, Veloso VG, Pilotto JH, Joao E, Nielsen-Saines K; NICHD HPTN 040 Study Team. Chlamydia and gonorrhea in HIV-infected pregnant women and infant HIV transmission. Sex Transm Dis. 2015 Oct;42(10):554-65. doi: 10.1097/OLQ.0000000000000340. PMID: 26372927; PMCID: PMC4571193
Date: 10/01/2015
A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness
Citation: Stein JH, Ribaudo, HJ, Hodis, HN, Brown TT, Tran TTT, Yan M, Lauer-Brodell E, Kelesidis T, McComsey GA, Dubé, MP, Murphy RL, Currier, JS. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS. 2015 Sep 10;29(14):1775-83. doi: 10.1097/QAD.0000000000000762. PMID: 26372383. PMCID: PMC4571277
Date: 09/10/2015
- ‹ First < 14 15 16 17 18 > Last ›